Which has better valuation and earnings, IBRX or HCM?

HUTCHMED has higher revenue and earnings than ImmunityBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 64.53 -$351.40M -$0.85 N/A HUTCHMED $548.51M 3.46 $456.91M N/A N/A

Is IBRX or HCM more profitable?

HUTCHMED has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% HUTCHMED N/A N/A N/A

Which has higher earnings & valuation, QGEN or HCM?

HUTCHMED has lower revenue, but higher earnings than Qiagen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.65 $424.88M $1.91 19.39 HUTCHMED $548.51M 3.46 $456.91M N/A N/A

Is QGEN or HCM more profitable?

Qiagen has a net margin of 19.16% compared to HUTCHMED's net margin of 0.00%. Qiagen's return on equity of 14.40% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% HUTCHMED N/A N/A N/A

Which has stronger valuation and earnings, PCVX or HCM?

HUTCHMED has higher revenue and earnings than Vaxcyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A HUTCHMED $548.51M 3.46 $456.91M N/A N/A

Is PCVX or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% HUTCHMED N/A N/A N/A

Which has higher earnings and valuation, HCM or IMVT?

HUTCHMED has higher revenue and earnings than Immunovant. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 3.46 $456.91M N/A N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is HCM or IMVT more profitable?

HUTCHMED's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Immunovant N/A -65.66% -59.88%

Which has higher earnings and valuation, LNTH or HCM?

HUTCHMED has lower revenue, but higher earnings than Lantheus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.23 $233.56M $4.15 24.15 HUTCHMED $548.51M 3.46 $456.91M N/A N/A

Is LNTH or HCM more profitable?

Lantheus has a net margin of 18.05% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 29.32% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% HUTCHMED N/A N/A N/A

HUTCHMED (HCM) Competitors

$10.87 +0.24 (+2.26%)

Closing price 04:00 PM Eastern

Extended Trading

$10.88 +0.02 (+0.14%)

As of 04:10 PM Eastern

Compare

HCM vs. IBRX, QGEN, PCVX, IMVT, and LNTH

Should you buy HUTCHMED stock or one of its competitors? MarketBeat compares HUTCHMED with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HUTCHMED include ImmunityBio (IBRX), Qiagen (QGEN), Vaxcyte (PCVX), Immunovant (IMVT), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does HUTCHMED compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 103.44%. HUTCHMED has a consensus price target of $16.80, indicating a potential upside of 54.55%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

In the previous week, ImmunityBio had 5 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for ImmunityBio and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.32 beat ImmunityBio's score of 0.05 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmunityBio	Neutral
HUTCHMED	Positive

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 69.5% of ImmunityBio shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

HUTCHMED has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than ImmunityBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	64.53	-$351.40M	-$0.85	N/A
HUTCHMED	$548.51M	3.46	$456.91M	N/A	N/A

Summary

HUTCHMED beats ImmunityBio on 8 of the 14 factors compared between the two stocks.

How does HUTCHMED compare to Qiagen?

Qiagen (NYSE:QGEN) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

HUTCHMED has lower revenue, but higher earnings than Qiagen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.65	$424.88M	$1.91	19.39
HUTCHMED	$548.51M	3.46	$456.91M	N/A	N/A

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Qiagen had 2 more articles in the media than HUTCHMED. MarketBeat recorded 3 mentions for Qiagen and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.32 beat Qiagen's score of 0.43 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
Qiagen	Neutral
HUTCHMED	Positive

Qiagen presently has a consensus price target of $44.98, indicating a potential upside of 21.46%. HUTCHMED has a consensus price target of $16.80, indicating a potential upside of 54.55%. Given HUTCHMED's higher probable upside, analysts clearly believe HUTCHMED is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to HUTCHMED's net margin of 0.00%. Qiagen's return on equity of 14.40% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
HUTCHMED	N/A	N/A	N/A

Summary

Qiagen beats HUTCHMED on 11 of the 14 factors compared between the two stocks.

How does HUTCHMED compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Vaxcyte currently has a consensus price target of $86.00, indicating a potential upside of 89.34%. HUTCHMED has a consensus price target of $16.80, indicating a potential upside of 54.55%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vaxcyte is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

HUTCHMED's return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
HUTCHMED	N/A	N/A	N/A

Vaxcyte has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

HUTCHMED has higher revenue and earnings than Vaxcyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
HUTCHMED	$548.51M	3.46	$456.91M	N/A	N/A

In the previous week, Vaxcyte had 5 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Vaxcyte and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.32 beat Vaxcyte's score of 0.96 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaxcyte	Positive
HUTCHMED	Positive

Summary

HUTCHMED beats Vaxcyte on 7 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Immunovant?

HUTCHMED (NASDAQ:HCM) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Immunovant had 4 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Immunovant and 1 mentions for HUTCHMED. Immunovant's average media sentiment score of 1.60 beat HUTCHMED's score of 1.32 indicating that Immunovant is being referred to more favorably in the news media.

Company	Overall Sentiment
HUTCHMED	Positive
Immunovant	Very Positive

HUTCHMED has higher revenue and earnings than Immunovant.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	3.46	$456.91M	N/A	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

HUTCHMED's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Immunovant	N/A	-65.66%	-59.88%

HUTCHMED has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

HUTCHMED presently has a consensus target price of $16.80, suggesting a potential upside of 54.55%. Immunovant has a consensus target price of $37.33, suggesting a potential upside of 19.73%. Given HUTCHMED's higher probable upside, analysts plainly believe HUTCHMED is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

HUTCHMED beats Immunovant on 7 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Lantheus?

Lantheus (NASDAQ:LNTH) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

Lantheus has a net margin of 18.05% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 29.32% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
HUTCHMED	N/A	N/A	N/A

99.1% of Lantheus shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HUTCHMED has lower revenue, but higher earnings than Lantheus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.15	24.15
HUTCHMED	$548.51M	3.46	$456.91M	N/A	N/A

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Lantheus currently has a consensus price target of $101.86, suggesting a potential upside of 1.61%. HUTCHMED has a consensus price target of $16.80, suggesting a potential upside of 54.55%. Given HUTCHMED's higher possible upside, analysts clearly believe HUTCHMED is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Lantheus had 3 more articles in the media than HUTCHMED. MarketBeat recorded 4 mentions for Lantheus and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.32 beat Lantheus' score of 0.65 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantheus	Positive
HUTCHMED	Positive

Summary

Lantheus beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCM vs. The Competition

Export

Metric	HUTCHMED	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.90B	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	N/A	18.99	24.49	23.62
Price / Sales	3.46	290.48	500.49	105.27
Price / Cash	4.03	118.24	42.36	56.09
Price / Book	1.52	8.00	10.43	6.70
Net Income	$456.91M	$23.89M	$3.56B	$337.26M
7 Day Performance	-3.89%	-3.49%	-1.38%	-1.41%
1 Month Performance	-17.21%	1.02%	0.86%	1.15%
1 Year Performance	-35.45%	34.39%	19.43%	22.61%

HUTCHMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCM HUTCHMED	3.2336 of 5 stars	$10.87 +2.3%	$16.80 +54.6%	-33.4%	$1.90B	$548.51M	N/A	1,796	Positive News
IBRX ImmunityBio	2.9961 of 5 stars	$7.24 -3.7%	$14.20 +96.1%	+110.8%	$7.88B	$113.29M	N/A	590
QGEN Qiagen	4.6028 of 5 stars	$36.16 -1.2%	$44.98 +24.4%	-22.3%	$7.54B	$2.10B	18.88	5,654	Short Interest Decrease
PCVX Vaxcyte	2.6471 of 5 stars	$48.91 -4.8%	$86.00 +75.8%	+26.0%	$7.42B	N/A	N/A	160	News Coverage
IMVT Immunovant	3.6999 of 5 stars	$32.86 -1.3%	$37.33 +13.6%	+94.0%	$6.75B	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCM) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HUTCHMED (HCM) Competitors

HCM vs. IBRX, QGEN, PCVX, IMVT, and LNTH

How does HUTCHMED compare to ImmunityBio?

Summary

How does HUTCHMED compare to Qiagen?

Summary

How does HUTCHMED compare to Vaxcyte?

Summary

How does HUTCHMED compare to Immunovant?

Summary

How does HUTCHMED compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HUTCHMED (HCM) Competitors

HCM vs. IBRX, QGEN, PCVX, IMVT, and LNTH

How does HUTCHMED compare to ImmunityBio?

Do analysts rate IBRX or HCM?

Which has more risk & volatility, IBRX or HCM?

Does the media prefer IBRX or HCM?

Do institutionals and insiders believe in IBRX or HCM?

Is IBRX or HCM more profitable?

Which has better valuation and earnings, IBRX or HCM?

Summary

How does HUTCHMED compare to Qiagen?

Which has higher earnings & valuation, QGEN or HCM?

Do institutionals & insiders have more ownership in QGEN or HCM?

Does the media prefer QGEN or HCM?

Do analysts prefer QGEN or HCM?

Which has more risk & volatility, QGEN or HCM?

Is QGEN or HCM more profitable?

Summary

How does HUTCHMED compare to Vaxcyte?

Do analysts rate PCVX or HCM?

Do institutionals and insiders believe in PCVX or HCM?

Is PCVX or HCM more profitable?

Which has more risk & volatility, PCVX or HCM?

Which has stronger valuation and earnings, PCVX or HCM?

Does the media favor PCVX or HCM?

Summary

How does HUTCHMED compare to Immunovant?

Does the media favor HCM or IMVT?

Which has higher earnings and valuation, HCM or IMVT?

Is HCM or IMVT more profitable?

Which has more risk and volatility, HCM or IMVT?

Do insiders & institutionals have more ownership in HCM or IMVT?

Do analysts recommend HCM or IMVT?

Summary

How does HUTCHMED compare to Lantheus?

Is LNTH or HCM more profitable?

Do institutionals and insiders believe in LNTH or HCM?

Which has higher earnings and valuation, LNTH or HCM?

Which has more volatility & risk, LNTH or HCM?

Do analysts prefer LNTH or HCM?

Does the media prefer LNTH or HCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools